论文部分内容阅读
目的:评估玻璃体内注射不同剂量康柏西普(conbercept)治疗早产儿视网膜病变(ROP)的效果。方法:前瞻性随机对照研究。分析2017年10月至2018年10月在郑州大学附属儿童医院确诊为阈前1型ROP 60例(120眼)的临床资料。患儿随机分为两组：低剂量组(0.15 mg/0.015 ml)和高剂量组(0.25 mg/0.025 ml)。主要观察指标为治疗总成功率，次要观察指标为单次治疗成功率及不良反应。结果:治疗总成功率为94.17%(113/120)。经1次或多次注药病情控制者，低剂量组26例(52眼)的成功率为94.23%(49/52)；高剂量组34例(68眼)的成功率为94.12%(64/68)。两组间成功率差异无统计学意义(n χ2＝0.026，n P＝0.979)。单次注药的成功率低剂量组为76.92%(40/52)，高剂量组为61.76%(42/68)。两组间单次注药的成功率差异无统计学意义(n χ2＝1.762，n P＝0.078)。n 结论:低剂量康柏西普治疗ROP的治愈率与高剂量康柏西普一致。“,”Objective:To evaluate the efficacy of intravitreal injection of different dose of conbercept for the treatment of retinopathy of prematurity (ROP).Methods:Prospective randomized controlled study. The clinical data of 120 eyes of 60 children of prethreshold type 1 ROP diagnosed in Children’s Hospital Affiliated to Zhengzhou University from Oct. 2017 to Oct. 2018 were analyzed. All cases were randomly divided into two groups, including low-dose group (0.15 mg/0.015 ml) and high-dose group (0.25 mg/0.025 ml). The main outcome measure was the total success rate of treatment, and the secondary outcome measures were the success rate of single treatment and adverse reactions.Results:The total success rate of treatment was 94.17% (113/120). In 52 eyes of 26 cases in the low-dose group, 49 eyes received one or more injections to control the disease, with a success rate of 94.23%. In 68 eyes of 34 children in the high-dose group, 64 eyes received one or more injections to control their condition, with a success rate of 94.12%. The difference was not statistically significant between the two groups (n χ2=0.026, n P=0.979). The success rate of single injection in low-dose group was 76.92% (40/52) and 61.76%(42/68) in the high-dose group. There is no statistically significant difference between the two groups (n χ2=1.762, n P=0.078).n Conclusion:The low-dose of conbercept is effective in the treatment of ROP, the care rate is the same as the high dose of that.